IBA Dosimetry Solution Used to Accept the First Varian Halcyon™ in the United States

IBA Dosimetry QA solutions used at The University of Pennsylvania to accept their new Halcyon linear accelerator.

IBA Dosimetry Radiation News Release Blue Phantom Halcyon

Bartlett, TN, USA, January 22nd, 2018 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces that longtime partner, The University of Pennsylvania, recipients of the first Varian Halcyon system in the United States, validated and accepted the system with their IBA Dosimetry Blue Phantom solution.

Chris Kennedy Ph.D. DABR, Medical Physicist, says: “We had a very good experience using our Blue Phantom solution to validate our Halcyon LINAC. We actually used the same equipment that Varian used when they did their original commissioning of the treatment planning system. The setup was very straightforward, and the flexibility of the myQA Accept software was essential for aligning the detector using the image-based methods necessary for Halcyon. The bulk of our validation work was done in 3 days.”

The University of Pennsylvania partnered with Varian during product development and received the very first clinical Halcyon in the world in September of 2017. With their Blue Phantom system, physicists at the University of Pennsylvania were able to perform an independent validation to accept the Halcyon and its TPS data and treated the first patient in the world that same month. Several members of IBA Dosimetry’s staff were on site to observe the physicists during the validation process. 

Doug Utter, Director of Sales, Americas, says: “IBA is very excited to collaborate with Varian Development Team and the University of Pennsylvania on the Halcyon LINAC. IBA has designed special tools and implemented new functionality that will allow physicist to efficiently and accurately perform all the required scanning for validating, acceptance and annual testing of the Halcyon system.”

About IBA Dosimetry

IBA Dosimetry innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at: www.iba-dosimetry.com


About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com


About The University of Pennsylvania and the Abramson Cancer Center

Penn Medicine’s Abramson Cancer Center, established in 1973, is the world leader in cancer research patient care, and education. The Department of Radiation Oncology is one of the largest and most respected programs in the world, and offers a full range of advanced treatment techniques, including proton therapy.